Not Just Another Index.
It’s The New Generation.®
We offer specialized solutions for investors seeking exposure to New Listings - a proxy for economic growth and innovation.
New: The IPOX® High Dividend 7% Strategy
An Innovative Index Strategy
combining Income & Growth!
Upcoming Global IPOs
The IPOX® Newsletters
IPOX® in the News
In a Reuters feature on how companies are navigating IPO plans during the U.S. government shutdown, IPOX® Research Associate Lukas Muehlbauer explained why biotech firms like MapLight are seizing this favorable market window despite regulatory delays. Muehlbauer noted that MapLight aims to get ahead of the SEC backlog, though the 20-day pricing lock limits flexibility. He added that biotech firms’ urgent funding needs make them prime candidates for this route.
Reuters reports that MapLight Therapeutics is targeting a $704.3 million valuation in its U.S. IPO, reflecting renewed investor appetite for biotech offerings. IPOX® CEO Josef Schuster described the move as “opportunistic”, citing the strong market climate for IPOs and heightened M&A activity in the sector. Schuster added that MapLight’s promising drug candidates and market momentum are likely to attract significant investor interest.
In a recent Reuters article, IPOX® CEO Josef Schuster commented on Cerebras Systems’ decision to withdraw its planned U.S. IPO, following the company’s $1.1 billion funding round. Schuster noted the move was “no surprise” given the recent capital raise, emphasizing it was a strategic decision rather than a reflection of market weakness, adding that U.S. IPO sentiment remains exceptionally strong amid renewed investor enthusiasm for AI-related offerings.
A U.S. government shutdown has halted SEC IPO processing, creating uncertainty just as the market was rebounding. While some deals may face delays, IPOX® research analyst Lukas Muehlbauer emphasized that strong investor demand and inflows into IPO-focused funds should sustain momentum once operations resume. “The best after-market performance in years will continue to lure companies to the market,” he noted.
Education provider Phoenix Education Partners, owner of the University of Phoenix, is targeting a valuation of up to $1.17B in its planned U.S. IPO. Backed by Apollo Global and Vistria Group, the firm seeks to raise $140.3M with shares priced between $31–33, listing on the NYSE under "PXED." IPOX® CEO Josef Schuster noted strong sentiment for U.S. IPOs, highlighting differences in PE-backed deals. The offering reflects renewed sponsor-led listing momentum.
The IPOX® Update
Global IPO markets are regaining momentum across regions, with billion-dollar deals in the U.S., Europe, Asia, and MENA. Highlights include Verisure’s €3.1B raise in Stockholm, MRI Software’s potential $10B U.S. float, and Ottobock’s €800M Frankfurt listing. Meanwhile, fintech Wealthfront, Navan, and University of Phoenix’s owner have filed in the U.S. Strong demand persists, though risks remain, as IPOX® analysts warn pricing discipline and U.S. government shutdown delays could stall activity.
Global IPO activity is surging across regions in 2025. In the U.S./Canada, Medline eyes a $5B blockbuster, Neptune Insurance targets $2.76B, and Brookfield-backed Rockpoint advances in Toronto, with IPOX® VP Kat Liu offering insights. Europe sees Kingspan and Deutsche Börse prepping listings, while Zijin Gold leads Asia-Pacific with a $3.2B Hong Kong float. MENA/Africa highlights Kenya Pipeline’s planned $1.15B IPO and Dubai’s ALEC, amid renewed momentum tracked by IPOX® benchmarks.
In the U.S., Netskope, StubHub, Pattern Group, and SoftBank’s PayPay highlight renewed activity, with IPOX® CEO Josef Schuster, VP Kat Liu, and Associate Lukas Muehlbauer providing insights on selectivity and market resilience. Europe is seeing momentum from Verisure, SMG, Ottobock, and SumUp, while Asia-Pacific is led by multi-billion offerings from Zijin Gold, Chery, and MMC Port. MENA activity includes real estate listings from Dubai Investments and ALEC Holdings.